[1] Parmiani G.Melanoma Cancer Stem Cells: Markers and Functions.Cancers (Basel). 2016;8(3): E34.[2] Islam F, Qiao B, Smith RA, et al. Cancer stem cell: fundamental experimental pathological concepts and updates. Exp Mol Pathol. 2015;98(2):184-191.[3] Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005;65(20):9328-9337.[4] Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science. 1977;197(4302):461-463.[5] Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730-737.[6] Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-111.[7] Shakhova O, Sommer L.Testing the cancer stem cell hypothesis in melanoma: the clinics will tell. Cancer Lett. 2013;338(1):74-81.[8] Lenkiewicz M, Li N, Singh SK. Culture and isolation of brain tumor initiating cells. Curr Protoc Stem Cell Biol. 2009; Chapter 3:Unit3.3. [9] Moore N, Houghton J, Lyle S. Slow-cycling therapy-resistant cancer cells. Stem Cells Dev. 2012;21(10): 1822-1830.[10] Fulawka L, Donizy P, Halon A. Cancer stem cells--the current status of an old concept: literature review and clinical approaches. Biol Res. 2014;47:66.[11] Roesch A.Melanoma stem cells. J Dtsch Dermatol Ges. 2015;13(2):118-124.[12] 文辉才,眭云鹏,简雪平,等.体外培养的人恶性黑色素瘤球体细胞干细胞特性观察[J].山东医药, 2016, 56(19):22-24.[13] Burgess R, Huang RP. Cancer Stem Cell Biomarker Discovery Using Antibody Array Technology. Adv Clin Chem. 2016;73:109-125.[14] Goede V, Klein C, Stilgenbauer S. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody. Oncol Res Treat. 2015;38(4):185-192.[15] Lee N, Barthel SR, Schatton T. Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking. Lab Invest. 2014;94(1):13-30.[16] Murphy GF, Wilson BJ, Girouard SD, et al. Stem cells and targeted approaches to melanoma cure. Mol Aspects Med. 2014;39:33-49.[17] Song H, Su X, Yang K, et al. CD20 Antibody-Conjugated Immunoliposomes for Targeted Chemotherapy of Melanoma Cancer Initiating Cells. J Biomed Nanotechnol. 2015;11(11):1927-1946.[18] Roudi R, Korourian A, Shariftabrizi A, et al. Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes. Cancer Invest. 2015;33(7):294-302.[19] Roudi R, Ebrahimi M, Sabet MN, et al. Comparative gene-expression profiling of CD133(+) and CD133(-) D10 melanoma cells. Future Oncol. 2015;11(17):2383-2393.[20] Zimmerer RM, Matthiesen P, Kreher F, et al. Putative CD133+ melanoma cancer stem cells induce initial angiogenesis in vivo. Microvasc Res. 2016;104:46-54.[21] Madjd Z, Erfani E, Gheytanchi E, et al. Expression of CD133 cancer stem cell marker in melanoma: a systematic review and meta-analysis.Int J Biol Markers. 2016;31(2): e118-125.[22] Rajabi Fomeshi M, Ebrahimi M, Mowla SJ, et al. CD133 Is Not Suitable Marker for Isolating Melanoma Stem Cells from D10 Cell Line. Cell J. 2016;18(1):21-27.[23] Lutz NW, Banerjee P, Wilson BJ, et al. Expression of Cell-Surface Marker ABCB5 Causes Characteristic Modifications of Glucose, Amino Acid and Phospholipid Metabolism in the G3361 Melanoma-Initiating Cell Line. PLoS One. 2016;11(8):e0161803.[24] Ma J, Lin JY, Alloo A, et al. Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun. 2010;402(4):711-717.[25] Wilson BJ, Saab KR, Ma J, et al. ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. Cancer Res. 2014;74(15): 4196-4207.[26] Civenni G, Walter A, Kobert N, et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 2011;71(8):3098-3109.[27] Redmer T, Welte Y, Behrens D, et al. The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells. PLoS One. 2014;9(5):e92596.[28] Cheli Y, Bonnazi VF, Jacquel A, et al. CD271 is an imperfect marker for melanoma initiating cells. Oncotarget. 2014; 5(14):5272-5283.[29] Buonaccorsi JN, Prieto VG, Torres-Cabala C, et al. Diagnostic utility and comparative immunohistochemical analysis of MITF-1 and SOX10 to distinguish melanoma in situ and actinic keratosis: a clinicopathological and immunohistochemical study of 70 cases. Am J Dermatopathol. 2014;36(2):124-130.[30] Graf SA, Busch C, Bosserhoff AK, et al. SOX10 promotes melanoma cell invasion by regulating melanoma inhibitory activity. J Invest Dermatol. 2014;134(8):2212-2220.[31] Shakhova O, Zingg D, Schaefer SM, et al. Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol. 2012;14(8):882-890.[32] Willis BC, Johnson G, Wang J, et al. SOX10: a useful marker for identifying metastatic melanoma in sentinel lymph nodes. Appl Immunohistochem Mol Morphol. 2015; 23(2):109-112.[33] Rappa G, Fodstad O, Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells. 2008;26(12): 3008-3017.[34] Schatton T, Schütte U, Frank NY, et al. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res. 2010;70(2):697-708.[35] Regad T. Molecular and cellular pathogenesis of melanoma initiation and progression. Cell Mol Life Sci. 2013;70(21): 4055-4065.[36] Santini R, Vinci MC, Pandolfi S, et al. Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells. Stem Cells. 2012;30(9): 1808-1818.[37] Onisim A, Achimas-Cadariu A, Vlad C, et al. Current insights into the association of Nestin with tumor angiogenesis. J BUON. 2015;20(3):699-706.[38] 李崇鑫,宋鑫.黑素瘤干细胞样细胞及其靶向治疗研究进展[J].中国肿瘤生物治疗杂志,2016,23(1):124-129.[39] Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A. 2013;110(3):972-977.[40] CSCO黑色素瘤专家委员会.中国黑色素瘤诊疗指南(2011版)[J].临床肿瘤学杂志,2012,17(2):159-171. |